Bio-Techne Corp (NASDAQ: TECH) on Friday, soared 0.14% from the previous trading day, before settling in for the closing price of $48.33. Within the past 52 weeks, TECH’s price has moved between $46.01 and $83.62.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 10.17% over the past five years. The company achieved an average annual earnings per share of 7.58%. With a float of $154.99 million, this company’s outstanding shares have now reached $156.76 million.
Let’s look at the performance matrix of the company that is accounted for 3100 employees. In terms of profitability, gross margin is 65.88%, operating margin of 16.97%, and the pretax margin is 13.48%.
Bio-Techne Corp (TECH) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Bio-Techne Corp is 1.13%, while institutional ownership is 104.61%. The most recent insider transaction that took place on Feb 14 ’25, was worth 122,691. In this transaction Director of this company sold 1,860 shares at a rate of $65.96, taking the stock ownership to the 1,976 shares. Before that another transaction happened on Feb 14 ’25, when Company’s Domestic Partner of Director proposed sale 1,860 for $65.96, making the entire transaction worth $122,691.
Bio-Techne Corp (TECH) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.44 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 7.58% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.27% during the next five years compared to 11.13% growth over the previous five years of trading.
Bio-Techne Corp (NASDAQ: TECH) Trading Performance Indicators
Bio-Techne Corp (TECH) is currently performing well based on its current performance indicators. A quick ratio of 2.58 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.28. Likewise, its price to free cash flow for the trailing twelve months is 34.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.82, a number that is poised to hit 0.51 in the next quarter and is forecasted to reach 2.07 in one year’s time.
Technical Analysis of Bio-Techne Corp (TECH)
Bio-Techne Corp (NASDAQ: TECH) saw its 5-day average volume 3.87 million, a positive change from its year-to-date volume of 1.98 million. As of the previous 9 days, the stock’s Stochastic %D was 56.07%. Additionally, its Average True Range was 2.14.
During the past 100 days, Bio-Techne Corp’s (TECH) raw stochastic average was set at 7.18%, which indicates a significant decrease from 28.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.36% in the past 14 days, which was higher than the 47.26% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $51.73, while its 200-day Moving Average is $67.00. Nevertheless, the first resistance level for the watch stands at $49.21 in the near term. At $50.01, the stock is likely to face the second major resistance level. The third major resistance level sits at $51.00. If the price goes on to break the first support level at $47.41, it is likely to go to the next support level at $46.42. Assuming the price breaks the second support level, the third support level stands at $45.62.
Bio-Techne Corp (NASDAQ: TECH) Key Stats
Market capitalization of the company is 7.59 billion based on 156,767K outstanding shares. Right now, sales total 1,159 M and income totals 168,110 K. The company made 316,180 K in profit during its latest quarter, and 22,590 K in sales during its previous quarter.
